Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus

European Journal of Neurology

Volumn 20, Issue 2, 2013, Pages 236-242

  Miyajima, M ^a   Nakajima, M ^a   Ogino, I ^a   Miyata, H ^a   Motoi, Y ^a   Arai, H ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Biomarker; Cerebrospinal fluid; Idiopathic normal pressure hydrocephalus; Soluble amyloid precursor protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA AMYLOID (1-42); SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NORMOTENSIVE HYDROCEPHALUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; TAU PROTEINS;

EID: 84872407604     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03781.x     Document Type: Article

References (33)

1. Adams RD, Fisher CM, Hakim S, Ojemann RG, Sweet WH. Symptomatic occult hydrocephalus with 'normal' cerebrospinal-fluid pressure. A treatable syndrome. N Engl J Med 1965; 273: 117-126.
2. Iseki C, Kawanami T, Nagasawa H, et al. Asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus on MRI (AVIM) in the elderly: a prospective study in a Japanese population. J Neurol Sci 2009; 277: 54-57.
3. Tanaka N, Yamaguchi S, Ishikawa H, Ishii H, Meguro K. Prevalence of possible idiopathic normal-pressure hydrocephalus in Japan: the Osaki-Tajiri project. Neuroepidemiology 2009; 32: 171-175.
4. Ishikawa M, Hashimoto M, Kuwana N, et al. Guidelines for management of idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 2008; 48: Suppl.
5. Meier U, Miethke C. Predictors of outcome in patients with normal-pressure hydrocephalus. J Clin Neurosci 2003; 10: 453-459.
6. Hamlet A, And M, Sid-Ahmed S, Askar B, Pasqualini E. Theoretical considerations on the pathophysiology of normal pressure hydrocephalus (NPH) and NPH-related dementia. Med Hypo 2006; 67: 115-123.
7. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulately physiology: a hypothesis. Lancet Neurol 2003; 2: 506-511.
8. Silverberg GD. Normal pressure hydrocephalus (NPH): ischaemia, CSF stagnation or both. Brain 2004; 127: 947-948.
9. Golomb J, Wisoff J, Miller DC, et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry 2000; 68: 778-781.
10. Leinonen V, Koivisto AM, Savolainen S, et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol 2010; 68: 446-453.
11. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
12. Wahlund LO, Barkhof F, Fazekas F, et al. European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32: 1318-1322.
13. Tullberg M, Rosengren L, Blomsterwall E, Karlsson JE, Wikkelso C. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus. Neurology 1998; 50: 1122-1127.
14. Blennow K, Wallin A, Agren H, Spenger C, Siegfreid J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26: 231-245.
15. Kapaki EN, Paraskevas GP, Tzerakis NG, et al. Cerebrospinal fluid tau, phosphor-tau181 and β-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol 2007; 14: 168-173.
16. Xu H, Sweeney D, Wang R, et al. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci U S A. 1997; 94: 3748-3752.
17. Hartmann T, Bieger SC, Brühl B, et al. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 1997; 3: 1016-1020.
18. Greenfield JP, Tsai J, Gouras GK, et al. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci U S A 1999; 96: 742-747.
19. Koo EH, Sisodia SS, Archer DR, et al. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 1990; 87: 1561-1565.
20. Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev 2008; 23: 15.
21. Taylor CJ, Ireland DR, Ballagh I, et al. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol Dis 2008; 31: 250-260.
22. Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 2003; 70: 1-32.
23. Kins S, Lauther N, Szodorai A, Beyreuther K. Subcellular trafficking of the amyloid precursor protein gene family and its pathogenic role in Alzheimer's disease. Neurodegener 2006; 3: 218-226.
24. Suenaga T, Ohnishi K, Nishimura M, Nakamura S, Akiguchi I, Kimura J. Bundles of amyloid precursor protein-immunoreactive axons in human cerebrovascular white matter lesions. Acta Neuropathol 1994; 87: 450-455.
25. Selnes P, Blennow K, Zetterberg H, et al. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res 2010; 7: 10.
26. Akai K, Uchigasaki S, Tanaka U, Komatsu A. Normal pressure hydrocephalus. Neuropathological study. Acta Pathol Jpn 1987; 37: 97-110.
27. Tullberg M, Hultin L, Ekholm S, Månsson JE, Fredman P, Wikkelsø C. White matter changes in normal pressure hydrocephalus and Binswanger disease: specificity, predictive value and correlations to axonal degeneration and demyelination. Acta Neurol Scand 2002; 105: 417-426.
28. Tullberg M, Jensen C, Ekholm S, Wikkelsø C. Normal pressure hydrocephalus: vascular white matter changes on MR images must not exclude patients from shunt surgery. AJNR Am J Neuroradiol 2001; 22: 1665-1673.
29. Tisell M, Tullberg M, Hellström P, Edsbagge M, Högfeldt M, Wikkelsö C. Shunt surgery in patients with hydrocephalus and white matter changes. J Neurosurg 2011; 114: 1432-1438.
30. Tarkowski E, Tullberg M, Fredman P, Wikkelsö C. Normal pressure hydrocephalus triggers intrathecal production of TNF-alpha. Neurobiol Aging 2003; 24: 707-714.
31. Lewczuk P, Kamrowski-Kruck H, Peters O, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010; 15: 138-145.
32. Ray B, Reyes PF, Lahiri DK. Biochemical studies in normal pressure hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau. J Psychiatr Res 2011; 45: 539-547.
33. Agren-Wilsson A, Lekman A, Sjoberg W, et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand 2007; 116: 333-339.